Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment
Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517543/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543722818338816 |
|---|---|
| author | Francesca Conti Francesca Conti Mattia Moratti Mattia Moratti Elena Sabattini Pier Luigi Zinzani Pier Luigi Zinzani |
| author_facet | Francesca Conti Francesca Conti Mattia Moratti Mattia Moratti Elena Sabattini Pier Luigi Zinzani Pier Luigi Zinzani |
| author_sort | Francesca Conti |
| collection | DOAJ |
| description | Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with the most commonly occurring of these being lymphoma, and is the most common cause of death in APDS patients. Management of APDS is complex and variable due to the heterogeneous nature of the disease and ranges from antimicrobial and immunosuppressant agents to haematopoetic stem cell transplantation. More recently, an increasing level of interest has been shown in the use of more targeted agents such as PI3Kδ-specific inhibitors. Here, we provide expert perspective on the suspected causality of a case of lymphoma observed in a 20-year-old female patient who was included in a clinical trial of leniolisib, a PI3K inhibitor. |
| format | Article |
| id | doaj-art-c85f5f5c4bbe4740a4e4c34c9ca89406 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-c85f5f5c4bbe4740a4e4c34c9ca894062025-01-13T06:11:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15175431517543Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatmentFrancesca Conti0Francesca Conti1Mattia Moratti2Mattia Moratti3Elena Sabattini4Pier Luigi Zinzani5Pier Luigi Zinzani6Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ItalySpecialty School of Paediatrics-Alma Mater Studiorum, University of Bologna, Bologna, ItalyDepartment of Systems Medicine, University of Tor Vergata, Rome, ItalyHaematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ItalyIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, ItalyActivated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with the most commonly occurring of these being lymphoma, and is the most common cause of death in APDS patients. Management of APDS is complex and variable due to the heterogeneous nature of the disease and ranges from antimicrobial and immunosuppressant agents to haematopoetic stem cell transplantation. More recently, an increasing level of interest has been shown in the use of more targeted agents such as PI3Kδ-specific inhibitors. Here, we provide expert perspective on the suspected causality of a case of lymphoma observed in a 20-year-old female patient who was included in a clinical trial of leniolisib, a PI3K inhibitor.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517543/fullactivated PI3K delta syndrome (APDS)leniolisibHodgkin (cHL)PI3K inhibitorHodgkin lymphoma (HL) |
| spellingShingle | Francesca Conti Francesca Conti Mattia Moratti Mattia Moratti Elena Sabattini Pier Luigi Zinzani Pier Luigi Zinzani Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment Frontiers in Immunology activated PI3K delta syndrome (APDS) leniolisib Hodgkin (cHL) PI3K inhibitor Hodgkin lymphoma (HL) |
| title | Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment |
| title_full | Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment |
| title_fullStr | Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment |
| title_full_unstemmed | Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment |
| title_short | Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment |
| title_sort | expert insights on hodgkin s lymphoma development in an activated pi3k delta syndrome patient undergoing leniolisib treatment |
| topic | activated PI3K delta syndrome (APDS) leniolisib Hodgkin (cHL) PI3K inhibitor Hodgkin lymphoma (HL) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517543/full |
| work_keys_str_mv | AT francescaconti expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT francescaconti expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT mattiamoratti expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT mattiamoratti expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT elenasabattini expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT pierluigizinzani expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment AT pierluigizinzani expertinsightsonhodgkinslymphomadevelopmentinanactivatedpi3kdeltasyndromepatientundergoingleniolisibtreatment |